Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma
Recruiting now · Not applicable
Conditions studied: Advanced Hepatocellular Carcinoma, Chemotherapy, Stereotactic Body Radiotherapy
In brief
To determine the efficacy and safety of atezolizumab-bevacizumab combination therapy plus stereotactic body radiotherapy(SBRT) in patients with advanced hepatocellular carcinoma, Subjects will start SBRT for one or more primary cancers and/or metastatic lesions and no more than 5 sites within two month before and after the start date of atezolizumab-bevacizumab combination therapy. In this study, it is expected to improve the treatment response rate of atezolizumab-bevacizumab therapy, which is currently first-line chemotherapy but has a low treatment response rate.
Key facts
- Study ID
- NCT06595108
- Run by
- Yonsei University
- People needed
- 33
- Starts
- 2024-05-28
- Expected to finish
- 2028-03-27
- Last updated by the study team
- 2024-11-01
Who can join
Age: 19 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 19 to 80 years old
- Liver function Child-Pugh class A
- ECOG 0-1
- Patient clinically or pathologically diagnosed with hepatocellular carcinoma
- Advanced hepatocellular carcinoma that is inoperable
- Satisfies the dose limits for normal organs and lesions of an appropriate size to be included in the scope of radiotherapy.
You may not qualify if…
- Brain metastases
- Have a history of malignancy other than hepatocellular carcinoma within the last 5 years (except for malignancies with little risk of metastasis or death, e.g., adequately treated cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, tubular carcinoma in situ, or stage 1 uterine cancer.)
- Subjects with a high probability of untreated gastric or esophageal varices or bleeding
- Serious uncontrolled medical comorbidities
- History of liver transplant surgery
- Autoimmune liver disease
Where it is running
- Yongin Severance Hospital — Yongin-si, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.